
    
      The study included a Screening Period of up to 4 weeks, which coincided with a 2-week
      single-blind, placebo Run-in Period, a 24 week Treatment Period, and a 2-week Follow-up
      Period. The duration of the study was approximately 30 weeks. The planned number of
      participants (n=450) was not reached; actual enrollment consisted of 105 particpants. Due to
      low enrollment this study was terminated early by Takeda.
    
  